Aurobindo Pharma Unit Gets US FDA Warning Letter

Date: August 14, 2026

Regulatory Disclosure

This communication follows previous disclosures dated May 24, 2026 and February 27, 2026 regarding the same facility receiving Official Action Indicated (OAI) status by the US FDA.

Financial Impact Assessment

The company stated that there is no impact on existing supplies to the US markets from this facility. Unit I of Eugia Pharma Specialities Ltd. contributes approximately 2% to Aurobindo Pharma's overall group revenue.

Company Response

The Company remains committed to working closely with the US FDA and continues to enhance its compliance on an ongoing basis. The company will keep the stock exchanges informed about further developments.